1-(2-(benzyloxy)ethyl)-4-bromobenzene | 170991-34-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-(benzyloxy)ethyl)-4-bromobenzene
• 英文别名: 4-(2-benzyloxyethyl)-1-bromobenzene；1-bromo-4-(2-phenylmethoxyethyl)benzene
• CAS: 170991-34-1
• 化学式: C₁₅H₁₅BrO
• 分子量: 291.187
• InChiKey: DUVMFQYEWCGNPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-(benzyloxy)ethyl)-4-bromobenzene 生成 2-[4-(2-benzoyloxyethyl)benzyl]phenol
  参考文献：
  名称：

  GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES

  摘要：

  公开号：

  EP1270584B1
• 作为产物：
  描述：

  溴甲苯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 1-(2-(benzyloxy)ethyl)-4-bromobenzene
  参考文献：
  名称：

  1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

  摘要：

  公开号：

  EP1813611B1

文献信息

• [EN] METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE SYMPTÔMES NEUROLOGIQUES ASSOCIÉS À DES MALADIES LYSOSOMALES
  申请人：GENZYME CORP

  公开号：WO2021156769A1

  公开（公告）日：2021-08-12

  Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases. The methods include enhancing neuronal connectivity within the brain of a subject, increasing brain tissue volume, or preventing or delaying loss of brain tissue volume in a subject. Also provided are methods for monitoring the progression or regression of a neurological disorder, or assessing the onset of a neurological disorder, associated with a lysosomal storage disease, in which brain tissue volume of the subject is measured.

  提供了用于治疗或预防与溶酶体贮积病等相关的神经症状和疾病的方法。这些方法包括增强受试者大脑内的神经连接、增加大脑组织体积，或者预防或延迟受试者大脑组织体积的丧失。还提供了用于监测神经疾病的进展或退化，或评估与溶酶体贮积病相关的神经疾病的发作的方法，其中测量了受试者的大脑组织体积。
• Optically active compound, liquid crystal composition containing the
  申请人：Canon Kabushiki Kaisha

  公开号：US05849217A1

  公开（公告）日：1998-12-15

  An optically active compound represented by the formula R.sub.1 --A.sub.1 --A.sub.2 --X.sub.1 --A.sub.3 --(CH.sub.2).sub.p --L--A.sub.4 --R.sub.2, in which R.sub.1 is F, CN or straight chain, branched or cyclic alkyl and R.sub.2 is H, F, CH or straight chain or branched alkyl; A.sub.3 is 1,4-phenylene, pyridine-2,5-diyl, pyrimidine-2,5-diyl, pyrazine-2,5-diyl, pyridazine-3,6-diyl, 1,4-cyclohexylene, 1,3-dioxane-2,5-diyl, 1,3-ditiane-2,5-diyl, thiophene-2,5-diyl, thiazole-2,5-diyl, thiaziazole-2,5-diyl, benzoxazole-2,5-diyl, benzoxazole-2,6-diyl, benzothiazole-2,5-diyl, benzothiazole-2,6-diyl, benzofuran-2,5-diyl, benzofuran-2,6-diyl, quinoxaline-2,6-diyl, quinoline-2,6-diyl, 2,6-naphthylene, indane-2,5-diyl, 2-alkylindane-2,5-diyl, indanone-2,6-diyl, 2-alkylindane-2,6-diyl, coumarane-2,5-diyl and 2-alkylcoumarane-2,5-diyl; A.sub.1, A.sub.2 and A.sub.4 are single bond or A.sub.3 ; X.sub.1 ' is a single bond, --COO--, --OCO--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH-- or --C.tbd.C--; p is an integer from 2 to 20; and L is optically active.

  化学式R.sub.1 --A.sub.1 --A.sub.2 --X.sub.1 --A.sub.3 --(CH.sub.2).sub.p --L--A.sub.4 --R.sub.2代表的一种光学活性化合物，其中R.sub.1为F、CN或直链、支链或环烷基，R.sub.2为H、F、CH或直链或支链烷基；A.sub.3为1,4-苯撑基、吡啶-2,5-二基、嘧啶-2,5-二基、吡嗪-2,5-二基、吡啶嗪-3,6-二基、1,4-环己撑基、1,3-二氧杂环戊烷-2,5-二基、1,3-二硫杂环戊烷-2,5-二基、噻吩-2,5-二基、噻唑-2,5-二基、噻二唑-2,5-二基、苯并噁唑-2,5-二基、苯并噁唑-2,6-二基、苯并噻唑-2,5-二基、苯并噻唑-2,6-二基、苯并呋喃-2,5-二基、苯并呋喃-2,6-二基、喹啉-2,6-二基、喹啉-2,6-二基、2,6-萘撑基、茚-2,5-二基、2-烷基茚-2,5-二基、茚酮-2,6-二基、2-烷基茚-2,6-二基、香豆素-2,5-二基和2-烷基香豆素-2,5-二基；A.sub.1、A.sub.2和A.sub.4为单键或A.sub.3；X.sub.1 '为单键、--COO--、--OCO--、--CH.sub.2 O--、--OCH.sub.2--、--CH.sub.2 CH.sub.2--、--CH.dbd.CH--或--C.tbd.C--；p为2到20的整数；L为光学活性。
• [EN] METHODS FOR TREATING PROTEINOPATHIES<br/>[FR] PROCÉDÉS DE TRAITEMENT DE PROTÉINOPATHIES
  申请人：GENZYME CORP

  公开号：WO2016145046A1

  公开（公告）日：2016-09-15

  This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson's disease, Alzheimer's disease or dementia with Lewy bodies.

  这份披露涉及一种治疗受试者蛋白病的方法，该方法包括向受试者施用有效量的环丙胺化合物。该披露还涉及一种减少、逆转或预防被诊断为患有蛋白病或有患蛋白病风险的受试者组织中蛋白聚集物积累的方法，该方法包括向受试者施用有效量的环丙胺化合物。还披露了一种包含环丙胺化合物的药物组合物，用于上述方法。蛋白病可能是突触核蛋白病或tau蛋白病，如帕金森病、阿尔茨海默病或带有Lewy小体的痴呆症。
• Inhibitor of cox
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040157891A1

  公开（公告）日：2004-08-12

  A compound of the formula (I): 1 wherein R 1 is cycloalkyl, etc; R 2 is (lower)alkoxy, etc; R 3 is (lower)alkylene, etc; R 4 is (lower)alkylene, etc; R 5 is hydroxy, etc; X is “O”, “S”, “SO”, or “SO 2 ”; Y is “CH” or “N”; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament.

  一种具有以下式（I）的化合物：其中R1是环烷基等；R2是（较低）烷氧基等；R3是（较低）烷基烯基等；R4是（较低）烷基烯基等；R5是羟基等；X为“O”、“S”、“SO”或“SO2”；Y为“CH”或“N”；n为0或1；或其药学上可接受的盐，可用作药物。
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE SYNTHASE DE GLUCOSYLCÉRAMIDE
  申请人：GENZYME CORP

  公开号：WO2014043068A1

  公开（公告）日：2014-03-20

  The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

  该发明涉及抑制葡萄糖鞘氨醇合成酶（GCS）的抑制剂，用于治疗代谢性疾病，如溶酶体贮积病，单独或与酶替代疗法、囊性疾病以及癌症的联合治疗。